Activation of presynaptic group II metabotropic glutamate receptors（mGluR2/3） inhibits drug reward and drug-seeking behavior, but the role of N-acetylaspartylglutamate（NAAG）, an agonist of endogenous mGluR2/3,in h...Activation of presynaptic group II metabotropic glutamate receptors（mGluR2/3） inhibits drug reward and drug-seeking behavior, but the role of N-acetylaspartylglutamate（NAAG）, an agonist of endogenous mGluR2/3,in heroin reward and heroin-seeking behavior remained unclear. Here, we aimed to explore the effects of exogenous NAAG on heroin self-administration and heroinseeking behavior. First, rats were trained to self-administer heroin under a fixed ratio 1（FR1） schedule for 10 days,then received NAAG（50 or 100μg/10 μL in each nostril）in the absence or presence of LY341495（1 mg/kg, i.p.）, an antagonist of mGluR2/3, on day 11 and the effects of NAAG on heroin self-administration under FR1 were recorded for 3 consecutive days. Motivation was assessed in heroin self-administration under a progressive ratio schedule on day 11 in another 5 groups with the same doses of NAAG. Additional rats were withdrawn for 14 days after 14 days of heroin self-administration, then received the same pharmacological pretreatment and were tested for heroin-seeking behaviors induced by heroin priming or cues. The results showed that intranasal administration of NAAG significantly decreased intravenous heroin selfadministration on day 12, but not on day 11. Pretreatment with LY341495 prior to testing on day 12 prevented the inhibitory effect of NAAG on heroin reinforcement. The break-point for reward motivation was significantly reduced by NAAG. Moreover, NAAG also significantly inhibited the heroin-seeking behaviors induced by heroinpriming or cues and these were restored by pretreatment with LY341495. These results demonstrated that NAAG,via activation of presynaptic mGluR2/3, attenuated the heroin reinforcement, heroin motivational value, and heroin-seeking behavior, suggesting that it may be used as an adjunct treatment for heroin addiction.展开更多
基金supported by the National Basic Research Program of China(2015CB553504)the National Natural Science Foundation of China(81471350 and 81671321)the Natural Science Foundation of Ningbo Municipality,Zhejiang Province,China(2015A610193)
文摘Activation of presynaptic group II metabotropic glutamate receptors（mGluR2/3） inhibits drug reward and drug-seeking behavior, but the role of N-acetylaspartylglutamate（NAAG）, an agonist of endogenous mGluR2/3,in heroin reward and heroin-seeking behavior remained unclear. Here, we aimed to explore the effects of exogenous NAAG on heroin self-administration and heroinseeking behavior. First, rats were trained to self-administer heroin under a fixed ratio 1（FR1） schedule for 10 days,then received NAAG（50 or 100μg/10 μL in each nostril）in the absence or presence of LY341495（1 mg/kg, i.p.）, an antagonist of mGluR2/3, on day 11 and the effects of NAAG on heroin self-administration under FR1 were recorded for 3 consecutive days. Motivation was assessed in heroin self-administration under a progressive ratio schedule on day 11 in another 5 groups with the same doses of NAAG. Additional rats were withdrawn for 14 days after 14 days of heroin self-administration, then received the same pharmacological pretreatment and were tested for heroin-seeking behaviors induced by heroin priming or cues. The results showed that intranasal administration of NAAG significantly decreased intravenous heroin selfadministration on day 12, but not on day 11. Pretreatment with LY341495 prior to testing on day 12 prevented the inhibitory effect of NAAG on heroin reinforcement. The break-point for reward motivation was significantly reduced by NAAG. Moreover, NAAG also significantly inhibited the heroin-seeking behaviors induced by heroinpriming or cues and these were restored by pretreatment with LY341495. These results demonstrated that NAAG,via activation of presynaptic mGluR2/3, attenuated the heroin reinforcement, heroin motivational value, and heroin-seeking behavior, suggesting that it may be used as an adjunct treatment for heroin addiction.
